Effects of Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: Review of recently completed randomised, controlled trials

International Journal of Psychiatry in Clinical Practice

Volumn 17, Issue SUPPL.1, 2013, Pages 8-14

  Ihl, Ralf ^a  

^a Krankenhaus Maria Hilf   (Germany)

Author keywords

Clinical trials; Dementia; Efficacy; Ginkgo biloba extract EGb 761 ; Review

Indexed keywords

DONEPEZIL; GINKGO BILOBA EXTRACT; PLACEBO;

ALZHEIMER DISEASE; BEHAVIOR; COGNITION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MULTIINFARCT DEMENTIA; NEUROPSYCHIATRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMPTOM; TREATMENT DURATION;

ACTIVITIES OF DAILY LIVING; DEMENTIA; GINKGO BILOBA; HUMANS; MULTICENTER STUDIES AS TOPIC; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PHYTOTHERAPY; PLACEBOS; PLANT EXTRACTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84884785510     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2013.814796     Document Type: Review

References (47)

1. Abdel-Kader R, Hauptmann S, Keil U, Scherping I, Leuner K, Eckert A, Muller WE. 2007. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res 56 : 493-502. (Pubitemid 350148165)
2. Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R. 2000a. Th e Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 12 : 1882-1890. (Pubitemid 30348827)
3. Bastianetto S, Zheng WH, Quirion R. 2000b. Th e Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its fl avonoid constituents and protein kinase C. J Neurochem 74 : 2268-2277. (Pubitemid 30314201)
4. Berr C, Wancata J, Ritchie K. 2005. Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol 15: 463-471. (Pubitemid 40943549)
5. Birks J, Grimley Evans J. 2009. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (1): CD003120.
6. Bornh ö ft G, Maxion-Bergemann S, Wolf U, Kienle GS, Michalsen A, Vollmar HC, et al. 2006, Checklist for the qualitative evaluation of clinical studies with particular focus on external validity and model validity. BMC Med Res Methodol, 6, 56.
7. Br å ne G, Gottfries CG, Winblad B. 2001. Th e GBS scale: validity, reliability and application in anti-dementia drug trials. Dement Geriatr Cogn Disord 12: 1-14. (Pubitemid 32010737)
8. Caldron PH, Gavrilova SI, Kropf S. 2012. Why (not) go east Comparison of fi ndings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world. Drug Des Devel Th er 6 : 53-60.
9. Cummings JL. 1997. Th e Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 48: S10-S16. (Pubitemid 27232698)
10. Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES Jr, Cox NJ, et al. 2010. National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline. Ann Intern Med 153: 176-181.
11. Eckert A, Keil U, Kressmann S, Schindowski K, Leutner S, Leutz S, Muller WE. 2003. Eff ects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry 36 : S15-S23. (Pubitemid 37047004)
12. Ernst E, Pittler MH. 2005. Ginkgo biloba for vascular dementia and Alzheimer ' s disease: updated systematic review of doubleblind, placebo-controlled, randomized trials. Perfusion 18: 388-392. (Pubitemid 43104438)
13. Hamilton M. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6: 278-296.
14. Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefk e S. 2012. Ginkgo biloba extract EGb 761in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confi rm the effi cacy and safety of a daily dose of 240 mg. J Psychiatr Res 46: 716-723.
15. Hoerr R. 2003. Behavioural and psychological symptoms of dementia (BPSD): eff ects of EGb 761. Pharmacopsychiatry 36: S56-S61. (Pubitemid 37047010)
16. Ihl R, Bachinskaya N, Korczyn AD, Vakhapova V, Tribanek M, Hoerr R, Napryeyenko O ; on behalf of the GSG. 2010. Effi cacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry 26 : 1186-1194.
17. Ihl R, Grass-Kapanke B, Janner M, Weyer G. 1999. Neuropsychometric tests in cross sectional and longitudinal studies-a regression analysis of ADAS-cog, SKT and MMSE. Pharmacopsychiatry 32 : 248-254.
18. Ihl R, Grass-Kapanke B, Lahrem P, Brinkmeyer J, Fischer S, Gaab N, Kaupmannsennecke C. 2000. Entwicklung und Validierung eines Tests zur Fruherkennung der Demenz mit Depressionsabgrenzung (TFDD). Fortschr Neurol Psychiatr 68: 413-422.
19. Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller H-J, et al. 2011. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias. World J Biol Psychiatry 12: 2-32.
20. Janßen IM, Sturtz S, Skipka G, Zentner A, Velasco Garrido M, Busse R. 2010. Ginkgo biloba in Alzheimer ' s disease: a systematic review. Wien Med Wochenschr 160: 539-546.
21. Kim YS, Nibbelink DW, Overall JE. 1993. Factor structure and scoring of the SKT test battery. J Clin Psychol 49: 61-71. (Pubitemid 23060006)
22. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. 2001. Midlife vascular risk factors and Alzheimer ' s disease in later life: longitudinal, population based study. BMJ 322 : 1447-1451. (Pubitemid 32575406)
23. Kö ltringer P, Langsteger W, Eber O 1995, Dose-dependent hemorheological eff ects and microcirulatory modifi cations following intravenous administration of Ginkgo biloba special extract EGb 761. Clin Hemorheol 15, 649-656.
24. Korczyn AD. 2002. Mixed dementia-the most common cause of dementia. Ann N Y Acad Sci 977: 129-134. (Pubitemid 35418145)
25. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. 2000. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 : S4-S9. (Pubitemid 30390598)
26. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. 2005. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65: 545-551. (Pubitemid 41170713)
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. 1984. Clinical diagnosis of Alzheimer ' s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer ' s Disease. Neurology 34: 939-944. (Pubitemid 14076461)
28. Mega MS, Masterman DM, O ' Connor SM, Barclay TR, Cummings JL. 1999. Th e spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 56 : 1388-1393. (Pubitemid 29519856)
29. Napryeyenko O, Borzenko I, Group G-NS. 2007. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung 57: 4-11. (Pubitemid 46212982)
30. Ramassamy C, Longpre F, Christen Y. 2007. Ginkgo biloba extract (EGb 761) in Alzheimer ' s disease: is there any evidence Curr Alzheimer Res 4: 253-262. (Pubitemid 47025423)
31. Reisberg B, Finkel S, Overall J, Schmidt-Gollas N, Kanowski S, Lehfeld H, et al. 2001. Th e Alzheimer ' s disease activities of daily living international scale (ADL-IS). Int Psychogeriatr 13: 163-181. (Pubitemid 32703329)
32. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. 1993. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43: 250-260. (Pubitemid 23060253)
33. Rosen WG. 1980. Verbal fl uency in aging and dementia. J Clin Neuropsychol 2: 135-146.
34. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. 2007. Mixed brain pathologies account for most dementia cases in communitydwelling older persons. Neurology 69: 2197-2204. (Pubitemid 350294674)
35. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. 2005. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer ' s type. Curr Alzheimer Res 2: 541-551. (Pubitemid 41703672)
36. Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, et al. 2005. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess 9 : 1-93, iii-iv.
37. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. 1997. Brain infarction and the clinical expression of Alzheimer disease. Th e Nun Study. JAMA 277: 813-817. (Pubitemid 27111317)
38. Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. 2008. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 23 : 170-177. (Pubitemid 351308497)
39. Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, Grafman JH. 1989. Clock drawing in Alzheimer ' s disease. A novel measure of dementia severity. J Am Geriatr Soc 37 : 725-729. (Pubitemid 19199790)
40. Tchantchou F, Xu Y, Wu Y, Christen Y, Luo Y. 2007. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer ' s disease. FASEB J 21 : 2400-2408. (Pubitemid 47230670)
41. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. 2003. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348: 1215-1222. (Pubitemid 36359297)
42. Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. 2010. Eff ects of Ginkgo biloba in dementia: systematic review and metaanalysis. BMC Geriatr 10 : 14.
43. Wimo A, Jonsson L, Gustavsson A, McDaid D, Ersek K, Georges J, et al. 2011. Th e economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int J Geriatr Psychiatry 26 : 825-832.
44. Wimo A, Winblad B, Aguero-Torres H, von Strauss E. 2003. Th e magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 17: 63-67.
45. Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, et al. 2006. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci 26: 13102-13113. (Pubitemid 44954628)
46. Yancheva S, Ihl R, Nikolova G, Panayotov P, Schlaefk e S, Hoerr R, Group GS. 2009. Ginkgo biloba extract EGb 761, donepezil or both combined in the treatment of Alzheimer ' s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health 13 : 183-190.
47. Yoshitake T, Yoshitake S, Kehr J. 2010. Th e Ginkgo biloba extract EGb 761and its main constituent fl avonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol 159: 659-668.